Selective estrogen receptor modulators inhibit hepatitis C virus infection at multiple steps of the virus life cycle

Microbes and Infection

Volumn 15, Issue 1, 2013, Pages 45-55

  Murakami, Yuko ^a   Fukasawa, Masayoshi ^a   Kaneko, Yukihiro ^a   Suzuki, Tetsuro ^a   Wakita, Takaji ^a   Fukazawa, Hidesuke ^a  

^a NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

Author keywords

HCV; SERM (Selective estrogen receptor modulator); Tamoxifen

Indexed keywords

ANTIESTROGEN; CLOMIFENE; NONSTRUCTURAL PROTEIN 5A; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; VIRUS RNA;

ARTICLE; DRUG SCREENING; GENE DOSAGE; HEPATITIS C; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; STOMATITIS; VIRAL GENETICS; VIRUS ATTACHMENT; VIRUS CULTURE; VIRUS ENTRY; VIRUS REPLICATION;

CELL LINE, TUMOR; ENDOCYTOSIS; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HUMANS; RNA, MESSENGER; RNA, VIRAL; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN; VIRAL NONSTRUCTURAL PROTEINS; VIRUS PHYSIOLOGICAL PROCESSES;

HEPATITIS C VIRUS; VESICULAR STOMATITIS VIRUS;

EID: 84871795820     PISSN: 12864579     EISSN: 1769714X     Source Type: Journal    
DOI: 10.1016/j.micinf.2012.10.003     Document Type: Article

References (29)

1. Wakita T., Pietschmann T., Kato T., Date T., Miyamoto M., Zhao Z., Murthy K., Habermann A., Krausslich H.G., Mizokami M., Bartenschlager R., Liang T.J. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat. Med. 2005, 11:791-796.
2. Murakami Y., Noguchi K., Yamagoe S., Suzuki T., Wakita T., Fukazawa H. Identification of bisindolylmaleimides and indolocarbazoles as inhibitors of HCV replication by tube-capture-RT-PCR. Antivir. Res. 2009, 83:112-117.
3. Kato T., Date T., Miyamoto M., Furusaka A., Tokushige K., Mizokami M., Wakita T. Efficient replication of the genotype 2a hepatitis C virus subgenomic replicon. Gastroenterology 2003, 125:1808-1817.
4. Date T., Kato T., Miyamoto M., Zhao Z., Yasui K., Mizokami M., Wakita T. Genotype 2a hepatitis C virus subgenomic replicon can replicate in HepG2 and IMY-N9 cells. J. Biol. Chem. 2004, 279:22371-22376.
5. Lohmann V., Korner F., Koch J., Herian U., Theilmann L., Bartenschlager R. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 1999, 285:110-113.
6. Fukazawa H., Mizuno S., Uehara Y. A microplate assay for quantitation of anchorage-independent growth of transformed cells. Anal. Biochem. 1995, 228:83-90.
7. Bartosch B., Dubuisson J., Cosset F.L. Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes. J. Exp. Med. 2003, 197:633-642.
8. Lavillette D., Tarr A.W., Voisset C., Donot P., Bartosch B., Bain C., Patel A.H., Dubuisson J., Ball J.K., Cosset F.L. Characterization of host-range and cell entry properties of the major genotypes and subtypes of hepatitis C virus. Hepatology 2005, 41:265-274.
9. Osborne C.K., Zhao H., Fuqua S.A. Selective estrogen receptor modulators: structure, function, and clinical use. J. Clin. Oncol. 2000, 18:3172-3186.
10. Wakeling A.E., Dukes M., Bowler J. A potent specific pure antiestrogen with clinical potential. Cancer Res. 1991, 51:3867-3873.
11. Biberger C., von Angerer E. 2-Phenylindoles with sulfur containing side chains. Estrogen receptor affinity, antiestrogenic potency, and antitumor activity. J. Steroid Biochem. Mol. Biol. 1996, 58:31-43.
12. Sun J., Huang Y.R., Harrington W.R., Sheng S., Katzenellenbogen J.A., Katzenellenbogen B.S. Antagonists selective for estrogen receptor alpha. Endocrinology 2002, 143:941-947.
13. Sciaky N., Presley J., Smith C., Zaal K.J., Cole N., Moreira J.E., Terasaki M., Siggia E., Lippincott-Schwartz J. Golgi tubule traffic and the effects of brefeldin A visualized in living cells. J. Cell Biol. 1997, 139:1137-1155.
14. Blanchard E., Belouzard S., Goueslain L., Wakita T., Dubuisson J., Wychowski C., Rouille Y. Hepatitis C virus entry depends on clathrin-mediated endocytosis. J. Virol. 2006, 80:6964-6972.
15. Meertens L., Bertaux C., Dragic T. Hepatitis C virus entry requires a critical postinternalization step and delivery to early endosomes via clathrin-coated vesicles. J. Virol. 2006, 80:11571-11578.
16. Tscherne D.M., Jones C.T., Evans M.J., Lindenbach B.D., McKeating J.A., Rice C.M. Time- and temperature-dependent activation of hepatitis C virus for low-pH-triggered entry. J. Virol. 2006, 80:1734-1741.
17. Op De Beeck A., Voisset C., Bartosch B., Ciczora Y., Cocquerel L., Keck Z., Foung S., Cosset F.L., Dubuisson J. Characterization of functional hepatitis C virus envelope glycoproteins. J. Virol. 2004, 78:2994-3002.
18. Bartosch B., Cosset F.L. Cell entry of hepatitis C virus. Virology 2006, 348:1-12.
19. Cormier E.G., Durso R.J., Tsamis F., Boussemart L., Manix C., Olson W.C., Gardner J.P., Dragic T. L-SIGN (CD209L) and DC-SIGN (CD209) mediate transinfection of liver cells by hepatitis C virus. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:14067-14072.
20. Cormier E.G., Tsamis F., Kajumo F., Durso R.J., Gardner J.P., Dragic T. CD81 is an entry coreceptor for hepatitis C virus. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:7270-7274.
21. Koutsoudakis G., Kaul A., Steinmann E., Kallis S., Lohmann V., Pietschmann T., Bartenschlager R. Characterization of the early steps of hepatitis C virus infection by using luciferase reporter viruses. J. Virol. 2006, 80:5308-5320.
22. Altan N., Chen Y., Schindler M., Simon S.M. Tamoxifen inhibits acidification in cells independent of the estrogen receptor. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:4432-4437.
23. Watashi K., Inoue D., Hijikata M., Goto K., Aly H.H., Shimotohno K. Anti-hepatitis C virus activity of tamoxifen reveals the functional association of estrogen receptor with viral RNA polymerase NS5B. J. Biol. Chem. 2007, 282:32765-32772.
24. Gastaminza P., Whitten-Bauer C., Chisari F.V. Unbiased probing of the entire hepatitis C virus life cycle identifies clinical compounds that target multiple aspects of the infection. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:291-296.
25. Chockalingam K., Simeon R.L., Rice C.M., Chen Z. A cell protection screen reveals potent inhibitors of multiple stages of the hepatitis C virus life cycle. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:3764-3769.
26. de Medina P., Favre G., Poirot M. Multiple targeting by the antitumor drug tamoxifen: a structure-activity study. Curr. Med. Chem. Anticancer Agents 2004, 4:491-508.
27. Prossnitz E.R., Arterburn J.B., Sklar L.A. GPR30: a G protein-coupled receptor for estrogen. Mol. Cell. Endocrinol. 2007, 265-266:138-142.
28. Thomas P., Pang Y., Filardo E.J., Dong J. Identity of an estrogen membrane receptor coupled to a G protein in human breast cancer cells. Endocrinology 2005, 146:624-632.
29. Dennis M.K., Burai R., Ramesh C., Petrie W.K., Alcon S.N., Nayak T.K., Bologa C.G., Leitao A., Brailoiu E., Deliu E., Dun N.J., Sklar L.A., Hathaway H.J., Arterburn J.B., Oprea T.I., Prossnitz E.R. In vivo effects of a GPR30 antagonist. Nat. Chem. Biol. 2009, 5:421-427.